CytRx Names New CFO

Los Angeles-based CytRx, a biopharmaceuticals firm which is developing small molecule drugs for the treatment of ALS, said earlier this week that it has appointed Mitchell K. Fogelman as the firm's CFO. Fogelman replaces Matthew Natalizio, who has left the firm. Fogelman was most recently at International Aluminum Corporation, and also has been at PricewaterhouseCoopers LLP. ALS (Amyotrophic lateral sclerosis) is often referred to as Lou Gehrig's disease. CytRx says that it is planning to enter a Phase IIb clinical trial pending FDA clearance of its lead compound. More information »